Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 127, Issue , 2018, Pages 6-14

  Arenas, M ^a   Rodriguez E ^a   Sahebkar, A ^b,c   Sabater, S ^d   Rizo, D ^a   Pallise O ^a   Hernandez M ^a   Riu, F ^a   Camps, J ^a   Joven, J ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Meta analysis; Oxidative stress; paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ACUTE MYELOID LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIVITY; DIGESTIVE SYSTEM CANCER; EFFECT SIZE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE GENITAL TRACT CANCER; GENOMIC INSTABILITY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MALIGNANT NEOPLASM; OXIDATIVE STRESS; PUBLISHING; REVIEW; SYSTEMATIC REVIEW; TUMOR PROMOTION; URINARY TRACT CANCER; CASE CONTROL STUDY; FEMALE; MALE; META ANALYSIS; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY;

ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 85046371547     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2018.04.005     Document Type: Review

References (38)

1. Afsar, C.U., Gunaldı M., Okuturlar, Y., Gedikbası A., Tiken, E.E., Kahraman, S., Karaca, F., Ercolak, V., Karabulut, M., Paraoxonase-1 and arylesterase activities in patients with colorectal cancer. Int. J. Clin. Exp. Med. 8 (2015), 21599–21604.
2. Ahmed, N.S., Shafik, N.M., Elraheem, O.A., Abou-Elnoeman, S.E., Association of paraoxonase-1(Q192R and L55M) gene polymorphisms and activity with colorectal cancer and effect of surgical intervention. Asian Pac. J. Cancer Prev. 16 (2015), 803–809.
3. Akçay, M.N., Polat, M.F., Yilmaz, I., Akçay, G., Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 50:Suppl 2 (2003), ccxxv–ccxxvii.
4. Akçay, M.N., Yilmaz, I., Polat, M.F., Akçay, G., Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 50:Suppl. 2 (2003), cclxxiii–cclxxv.
5. Antognelli, C., Del Buono, C., Ludovini, V., Gori, S., Talesa, V.N., Crinò L., Barberini, F., Rulli, A., CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer, 9, 2009, 115.
6. Arioz, D.T., Camuzcuoglu, H., Toy, H., Kurt, S., Celik, H., Erel, O., Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer. Eur. J. Gynaecol. Oncol. 30 (2009), 679–682.
7. Aviram, M., Rosenblat, M., Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 37 (2004), 1304–1316.
8. Aydin, O., Yacinkaya, S., Eren, E., Ergin, M., Eroglu, M., Yilmaz, N., Diminished arylesterase enzyme activity and total thiol levels in bladder cancer patients. Clin. Lab. 59 (2013), 1231–1237.
9. Balci, H., Genc, H., Papila, C., Can, G., Papila, B., Yanardag, H., Uzun, H., Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J. Clin. Lab. Anal. 26 (2012), 155–160.
10. Betteridge, D.J., What is oxidative stress?. Metabolism 49:Suppl (2) (2000), 3–8.
11. Bobin-Dubigeon, C., Jaffré I., Joalland, M.P., Classe, J.M., Campone, M., Hervé M., Bard, J.M., Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence. Clin. Biochem. 45 (2012), 1503–1505.
12. Bobin-Dubigeon, C., Lefrançois, A., Classe, J.M., Joalland, M.P., Bard, J.M., Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence. Clin. Biochem. 48 (2015), 1181–1183.
13. Bulbuller, N., Eren, E., Ellidag, H.Y., Oner, O.Z., Sezer, C., Aydin, O., Yılmaz, N., Diagnostic value of thiols, paraoxonase 1, arylesterase and oxidative balance in colorectal cancer in human. Neoplasma 60 (2013), 419–424.
14. Camps, J., Marsillach, J., Joven, J., The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 46 (2009), 83–106.
15. Camuzcuoglu, H., Arioz, D.T., Toy, H., Kurt, S., Celik, H., Erel, O., Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol. Oncol. 112 (2009), 481–485.
16. Çebi, A., Akgun, E., Esen, R., Demir, H., Çifci, A., The activities of serum paraoxonase and arylesterase and lipid profile in acute myeloid leukemia: preliminary results. Eur. Rev. Med. Pharmacol. Sci. 19 (2015), 4590–4594.
17. Chander, R., Kapoor, N.K., High density lipoprotein is a scavenger of superoxide anions. Biochem. Pharmacol. 40 (1990), 1663–1665.
18. Costa, L.G., Cole, T.B., Vitalone, A., Furlong, C.E., Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin. Chim. Acta 352 (2005), 37–47.
19. Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
20. Elkiran, E.T., Mar, N., Aygen, B., Gursu, F., Karaoglu, A., Koca, S., Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer, 7, 2007, 48.
21. Ellidag, H.Y., Aydin, O., Eren, E., Yilmaz, N., Ergin, M., Decreased HDL-dependent paraoxonase and arylesterase enzyme activity may indicate a worse prognosis in multiple myeloma. Asian Pac. J. Cancer Prev. 15 (2014), 9847–9851.
22. Eroglu, M., Yilmaz, N., Yalcinkaya, S., Ay, N., Aydin, O., Sezer, C., Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients. Kaohsiung J. Med. Sci. 29 (2013), 368–373.
23. Faridvand, Y., Oskuyi, A.E., Khadem-Ansari, M.H., Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma. Redox Rep. 21 (2016), 204–208.
24. Goswami, B., Tayal, D., Gupta, N., Mallika, V., Paraoxonase: a multifaceted biomolecule. Clin. Chim. Acta 410 (2009), 1–12.
25. Karaman, E., Uzun, H., Papila, I., Balci, H., Ozdilek, A., Genc, H., Yanardag, H., Papila, C., Serum paraoxonase activity and oxidative DNA damage in patients with laryngeal squamous cell carcinoma. J. Craniofac Surg. 21 (2010), 1745–1749.
26. Khersonsky, O., Tawfik, D.S., Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005), 6371–6382.
27. Korkmaz, H., Tabur, S., Özkaya, M., Aksoy, N., Yildiz, H., Akarsu, E., Paraoxonase and arylesterase activities in patients with papillary thyroid cancer. Scand. J. Clin. Lab. Invest. 75 (2015), 259–264.
28. Krzystek-Korpacka, M., Boehm, D., Matusiewicz, M., Diakowska, D., Grabowski, K., Gamian, A., Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes - connection with inflammation. Clin. Biochem. 41 (2008), 804–811.
29. Mackness, M., Mackness, B., Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene 567 (2015), 12–21.
30. Malik, U.U., Siddiqui, I.A., Hashim, Z., Zarina, S., Measurement of serum paraoxonase activity and MDA concentrations in patients suffering with oral squamous cell carcinoma. Clin. Chim. Acta 430 (2014), 38–42.
31. Michalak, S., Szubert, S., Moszynski, R., Sajdak, S., Szpurek, D., Serum arylesterase and paraoxonase activities in patients with ovarian tumors. Taiwan J. Obstet. Gynecol. 53 (2014), 490–493.
32. Ozturk, E., Balat, O., Dikensoy, E., Ugur, M.G., Ozcan, C., Aydin, A., Erel, O., Kul, S., No association between serum paraoxonase, arylesterase activities, and hydatidiform mole. Int. J. Gynecol. Cancer 21 (2011), 149–151.
33. Pierce, C.A., Software Review: Borenstein, M., Hedges, L.V., Higgins, J.P.T., Rothstein, H.R., Comprehensive meta-analysis (version 2.2.027) [computer software]. Englewood, NJ: Biostat. Organiz. Res. Meth. 2008:11 (2006), 188–191.
34. Ponce-Ruiz, N., Murillo-González, F.E., Rojas-García, A.E., Mackness, M., Bernal-Hernández, Y.Y., Barrón-Vivanco, B.S., González-Arias, C.A., Medina-Díaz, I.M., Transcriptional regulation of human paraoxonase 1 by nuclear receptors. Chem. Biol. Interact. 268 (2017), 77–84.
35. Précourt, L.P., Amre, D., Denis, M.C., Lavoie, J.C., Delvin, E., Seidman, E., Levy, E., The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 214 (2011), 20–36.
36. Sehitogulları A., Aslan, M., Sayır, F., Kahraman, A., Demir, H., Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma. Redox Rep. 19 (2014), 199–205.
37. Vecka, M., Jáchymová M., Vávrová L., Kodydková J., Macášek, J., Urbánek, M., Krechler, T., Slabý A., Dušková J., Muravská A., Zák, A., Paraoxonase-1 (PON1) status in pancreatic cancer: relation to clinical parameters. Folia Biol (Praha) 58 (2012), 231–237.
38. Wells, G.A.S.B., O'Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available from: 2009 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.